February 7, 2014
A New Tide Approaches
Simeprevir and sofosbuvir both represent a further step in the evolution of more effective, less-toxic HCV treatment options. But they, too, are just the beginning. Numerous direct-acting antiretrovirals are currently moving through the latter stage of the development pipeline, suggesting that the treatment landscape by early 2015 may look as different from the present as the present does from just a few years earlier.
For the notoriously hard-to-treat HCV genotype 1 in particular, Cox states: "It's hard to predict, but right now in advanced testing, there are some combinations that are inteferon-sparing" yet have very high sustained virologic response rates -- and may not even require the use of ribavirin.
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|This Week in HIV Research: "Can Opener" Molecule Exposes HIV, and How Much Does HIV Age You?|
|More Age-Related Illnesses in Older People With HIV Than Comparable HIV-Negatives|
|CROI 2015: The Future of Pre-Exposure Prophylaxis (Video)|
|New HIV Treatment Guidelines, and the End of an Era|
|This Week in HIV Research: Another Route for Gene Therapy; Drugmaker and University Team Up for HIV Cure|
|HIV-Positive Individuals on Treatment Lose More Years of Life to Smoking Than to HIV|